Plasma mevalonic acid exposure as a pharmacodynamic biomarker of fluvastatin/atorvastatin in healthy volunteers
In conclusion, the data show that the plasma exposure of MVL represents a reliable pharmacodynamic parameter for PK-PD (pharmacokinetic-pharmacodynamic) studies of fluvastatin in multiple doses and atorvastatin in a single dose. (Source: Journal of Pharmaceutical and Biomedical Analysis)
Source: Journal of Pharmaceutical and Biomedical Analysis - January 25, 2020 Category: Drugs & Pharmacology Source Type: research
Cerivastatin for lowering lipids.
CONCLUSIONS: The LDL cholesterol, total cholesterol, and triglyceride lowering effect of cerivastatin was linearly dependent on dose. Cerivastatin log dose-response data were linear over the commonly prescribed dose range. Based on an informal comparison with fluvastatin, atorvastatin and rosuvastatin, cerivastatin was about 250-fold more potent than fluvastatin, 20-fold more potent than atorvastatin and 5.5-fold more potent than rosuvastatin in reducing LDL cholesterol, and 233-fold greater potency than fluvastatin, 18-fold greater potency than atorvastatin and six-fold greater potency than rosuvastatin at reducing total ...
Source: Cochrane Database of Systematic Reviews - January 24, 2020 Category: General Medicine Authors: Adams SP, Tiellet N, Alaeiilkhchi N, Wright JM Tags: Cochrane Database Syst Rev Source Type: research
Antifungal effects of statins
In this study, we reviewed in-vitro and in-vivo studies, as well as clinical reports pertaining to the antifungal efficacy of statins. In addition, we have addressed various modulators of statin anti-fungal activity and the potential mechanisms responsible for their anti-fungal effects. In general, statins do possess anti-fungal activity, targeting a broad spectrum of fungal organisms including human opportunistic pathogens such as Candida spp. and Zygomycetes, Dermatophytes, alimentary toxigenic species such as Aspergillus spp., and fungi found in device implants such as Saccharomyces cerevisiae. Statins have been shown t...
Source: Pharmacology and Therapeutics - January 16, 2020 Category: Drugs & Pharmacology Source Type: research
Fluvastatin is effective against thymic carcinoma
Publication date: 1 January 2020Source: Life Sciences, Volume 240Author(s): Keitaro Hayashi, Yoshimasa Nakazato, Noriaki Morito, Mizuki Sagi, Tomoe Fujita, Naohiko Anzai, Masayuki ChidaAbstractAimsThymic carcinoma is a rare epithelial tumor, for which, optimal pharmacotherapeutic methods have not yet been established. To develop new drug treatments for thymic carcinoma, we investigated the effects of fluvastatin-mediated pharmacological inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) on thymic carcinoma.Main methodsThymic carcinoma tissue was surgically excised and HMGCR expression was assessed by imm...
Source: Life Sciences - November 29, 2019 Category: Biology Source Type: research
Transdermal delivery of fluvastatin sodium via tailored spanlastic nanovesicles: mitigated Freund's adjuvant-induced rheumatoid arthritis in rats through suppressing p38 MAPK signaling pathway.
Authors: El Menshawe SF, Nafady MM, Aboud HM, Kharshoum RM, Elkelawy AMMH, Hamad DS
Abstract
The current study aimed to encapsulate fluvastatin sodium (FVS), a member of the statins family possessing pleiotropic effects in rheumatoid arthritis (RA), into spanlastic nanovesicles (SNVs) for transdermal delivery. This novel delivery could surmount FVS associated oral encumbrances such as apparent first-pass effect, poor bioavailability and short elimination half-life, hence, accomplishing platform for management of RA. To consummate this objective, FVS-loaded SNVs were elaborated by thin film hydration method...
Source: Drug Delivery - November 20, 2019 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
